PF 6647263

Drug Profile

PF 6647263

Alternative Names: PF 06647263; PF-0667263; PF-6647263

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Eph family receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 13 Apr 2016 Phase-I development is ongoing in USA
  • 01 Apr 2014 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV)
  • 03 Mar 2014 Preclinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top